High serum Hsp70 level predicts poor survival in colorectal cancer: Results obtained in an independent validation cohort

L. Gráf, Lóránd Barabás, Balázs Madaras, Nóra Garam, Éva Maláti, Laura Horváth, Z. Prohászka, Z. Horváth, Judit Kocsis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

BACKGROUND: Hsp70 plays important role in the development and progression of cancer. Previously we described the association between serum Hsp70 levels and mortality of colorectal cancer. OBJECTIVE: In this new prospective study we aimed to confirm and extend our previous findings in a larger cohort of patients, based on a longer follow-up period. METHODS: Two hundred and thirty-two patients diagnosed with colorectal cancer were enrolled in the study. Baseline serum Hsp70 level and classical biomarker levels were measured. Patients were treated according to stage of the tumor and follow-up lasted for a median 46.4 months. RESULTS:We found that serum Hsp70 concentrations increase significantly with stage of the disease (1.79; 2.23 and 3.21 ng/ml in stage I+II, III and IV respectively, p = 0.012 and 0.002, Mann-Whitney test) and with other known biomarkers of the disease. We managed to confirm our previous findings that high baseline serum Hsp70 level (> 1.64 ng/ml) predicted poor 5-year survival (risk of death HR: 1.94 CI: 1.294-2.909; univariate; HR: 2.418 CI: 1.373-4.258; multivariate Cox regression analysis) in the whole patient population and also in subgroups of stage IV and stage III disease. The strongest association was observed in women under age of 70 (HR: 8.12, CI: 2.02-35.84; p = 0.004; multivariate Cox regression). The power of this colorectal cancer prognostic model could be amplified by combining Hsp70 levels and inflammatory markers. Patients with high Hsp70, CRP and high baseline WBC or platelet count had 5-times higher risk of death (HR: 5.07 CI: 2.74-9.39, p < 0.0001; and HR: 4.98 CI: 3.08-8.06, p < 0.0001 respectively). CONCLUSIONS: These results confirm and validate our previous findings that serum Hsp70 is a useful biomarker of colorectal cancer.

Original languageEnglish
Pages (from-to)539-547
Number of pages9
JournalCancer Biomarkers
Volume23
Issue number4
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Colorectal Neoplasms
Survival
Serum
Biomarkers
Platelet Count
Neoplasms
Regression Analysis
Prospective Studies
Mortality
Population

Keywords

  • Colorectal cancer
  • CRP
  • Hsp70
  • Prognostic model
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Genetics
  • Cancer Research

Cite this

High serum Hsp70 level predicts poor survival in colorectal cancer : Results obtained in an independent validation cohort. / Gráf, L.; Barabás, Lóránd; Madaras, Balázs; Garam, Nóra; Maláti, Éva; Horváth, Laura; Prohászka, Z.; Horváth, Z.; Kocsis, Judit.

In: Cancer Biomarkers, Vol. 23, No. 4, 01.01.2018, p. 539-547.

Research output: Contribution to journalArticle

Gráf, L. ; Barabás, Lóránd ; Madaras, Balázs ; Garam, Nóra ; Maláti, Éva ; Horváth, Laura ; Prohászka, Z. ; Horváth, Z. ; Kocsis, Judit. / High serum Hsp70 level predicts poor survival in colorectal cancer : Results obtained in an independent validation cohort. In: Cancer Biomarkers. 2018 ; Vol. 23, No. 4. pp. 539-547.
@article{808a33f283fe44c3ab9615ef2ddef52e,
title = "High serum Hsp70 level predicts poor survival in colorectal cancer: Results obtained in an independent validation cohort",
abstract = "BACKGROUND: Hsp70 plays important role in the development and progression of cancer. Previously we described the association between serum Hsp70 levels and mortality of colorectal cancer. OBJECTIVE: In this new prospective study we aimed to confirm and extend our previous findings in a larger cohort of patients, based on a longer follow-up period. METHODS: Two hundred and thirty-two patients diagnosed with colorectal cancer were enrolled in the study. Baseline serum Hsp70 level and classical biomarker levels were measured. Patients were treated according to stage of the tumor and follow-up lasted for a median 46.4 months. RESULTS:We found that serum Hsp70 concentrations increase significantly with stage of the disease (1.79; 2.23 and 3.21 ng/ml in stage I+II, III and IV respectively, p = 0.012 and 0.002, Mann-Whitney test) and with other known biomarkers of the disease. We managed to confirm our previous findings that high baseline serum Hsp70 level (> 1.64 ng/ml) predicted poor 5-year survival (risk of death HR: 1.94 CI: 1.294-2.909; univariate; HR: 2.418 CI: 1.373-4.258; multivariate Cox regression analysis) in the whole patient population and also in subgroups of stage IV and stage III disease. The strongest association was observed in women under age of 70 (HR: 8.12, CI: 2.02-35.84; p = 0.004; multivariate Cox regression). The power of this colorectal cancer prognostic model could be amplified by combining Hsp70 levels and inflammatory markers. Patients with high Hsp70, CRP and high baseline WBC or platelet count had 5-times higher risk of death (HR: 5.07 CI: 2.74-9.39, p < 0.0001; and HR: 4.98 CI: 3.08-8.06, p < 0.0001 respectively). CONCLUSIONS: These results confirm and validate our previous findings that serum Hsp70 is a useful biomarker of colorectal cancer.",
keywords = "Colorectal cancer, CRP, Hsp70, Prognostic model, Survival",
author = "L. Gr{\'a}f and L{\'o}r{\'a}nd Barab{\'a}s and Bal{\'a}zs Madaras and N{\'o}ra Garam and {\'E}va Mal{\'a}ti and Laura Horv{\'a}th and Z. Proh{\'a}szka and Z. Horv{\'a}th and Judit Kocsis",
year = "2018",
month = "1",
day = "1",
doi = "10.3233/CBM-181683",
language = "English",
volume = "23",
pages = "539--547",
journal = "Cancer Biomarkers",
issn = "1574-0153",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - High serum Hsp70 level predicts poor survival in colorectal cancer

T2 - Results obtained in an independent validation cohort

AU - Gráf, L.

AU - Barabás, Lóránd

AU - Madaras, Balázs

AU - Garam, Nóra

AU - Maláti, Éva

AU - Horváth, Laura

AU - Prohászka, Z.

AU - Horváth, Z.

AU - Kocsis, Judit

PY - 2018/1/1

Y1 - 2018/1/1

N2 - BACKGROUND: Hsp70 plays important role in the development and progression of cancer. Previously we described the association between serum Hsp70 levels and mortality of colorectal cancer. OBJECTIVE: In this new prospective study we aimed to confirm and extend our previous findings in a larger cohort of patients, based on a longer follow-up period. METHODS: Two hundred and thirty-two patients diagnosed with colorectal cancer were enrolled in the study. Baseline serum Hsp70 level and classical biomarker levels were measured. Patients were treated according to stage of the tumor and follow-up lasted for a median 46.4 months. RESULTS:We found that serum Hsp70 concentrations increase significantly with stage of the disease (1.79; 2.23 and 3.21 ng/ml in stage I+II, III and IV respectively, p = 0.012 and 0.002, Mann-Whitney test) and with other known biomarkers of the disease. We managed to confirm our previous findings that high baseline serum Hsp70 level (> 1.64 ng/ml) predicted poor 5-year survival (risk of death HR: 1.94 CI: 1.294-2.909; univariate; HR: 2.418 CI: 1.373-4.258; multivariate Cox regression analysis) in the whole patient population and also in subgroups of stage IV and stage III disease. The strongest association was observed in women under age of 70 (HR: 8.12, CI: 2.02-35.84; p = 0.004; multivariate Cox regression). The power of this colorectal cancer prognostic model could be amplified by combining Hsp70 levels and inflammatory markers. Patients with high Hsp70, CRP and high baseline WBC or platelet count had 5-times higher risk of death (HR: 5.07 CI: 2.74-9.39, p < 0.0001; and HR: 4.98 CI: 3.08-8.06, p < 0.0001 respectively). CONCLUSIONS: These results confirm and validate our previous findings that serum Hsp70 is a useful biomarker of colorectal cancer.

AB - BACKGROUND: Hsp70 plays important role in the development and progression of cancer. Previously we described the association between serum Hsp70 levels and mortality of colorectal cancer. OBJECTIVE: In this new prospective study we aimed to confirm and extend our previous findings in a larger cohort of patients, based on a longer follow-up period. METHODS: Two hundred and thirty-two patients diagnosed with colorectal cancer were enrolled in the study. Baseline serum Hsp70 level and classical biomarker levels were measured. Patients were treated according to stage of the tumor and follow-up lasted for a median 46.4 months. RESULTS:We found that serum Hsp70 concentrations increase significantly with stage of the disease (1.79; 2.23 and 3.21 ng/ml in stage I+II, III and IV respectively, p = 0.012 and 0.002, Mann-Whitney test) and with other known biomarkers of the disease. We managed to confirm our previous findings that high baseline serum Hsp70 level (> 1.64 ng/ml) predicted poor 5-year survival (risk of death HR: 1.94 CI: 1.294-2.909; univariate; HR: 2.418 CI: 1.373-4.258; multivariate Cox regression analysis) in the whole patient population and also in subgroups of stage IV and stage III disease. The strongest association was observed in women under age of 70 (HR: 8.12, CI: 2.02-35.84; p = 0.004; multivariate Cox regression). The power of this colorectal cancer prognostic model could be amplified by combining Hsp70 levels and inflammatory markers. Patients with high Hsp70, CRP and high baseline WBC or platelet count had 5-times higher risk of death (HR: 5.07 CI: 2.74-9.39, p < 0.0001; and HR: 4.98 CI: 3.08-8.06, p < 0.0001 respectively). CONCLUSIONS: These results confirm and validate our previous findings that serum Hsp70 is a useful biomarker of colorectal cancer.

KW - Colorectal cancer

KW - CRP

KW - Hsp70

KW - Prognostic model

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85058513718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058513718&partnerID=8YFLogxK

U2 - 10.3233/CBM-181683

DO - 10.3233/CBM-181683

M3 - Article

C2 - 30452400

AN - SCOPUS:85058513718

VL - 23

SP - 539

EP - 547

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 4

ER -